Zonghui Ma

778 total citations
29 papers, 494 citations indexed

About

Zonghui Ma is a scholar working on Molecular Biology, Oncology and Civil and Structural Engineering. According to data from OpenAlex, Zonghui Ma has authored 29 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Civil and Structural Engineering. Recurrent topics in Zonghui Ma's work include Protein Degradation and Inhibitors (11 papers), Peptidase Inhibition and Analysis (6 papers) and Ubiquitin and proteasome pathways (4 papers). Zonghui Ma is often cited by papers focused on Protein Degradation and Inhibitors (11 papers), Peptidase Inhibition and Analysis (6 papers) and Ubiquitin and proteasome pathways (4 papers). Zonghui Ma collaborates with scholars based in China, United States and United Kingdom. Zonghui Ma's co-authors include Yifan Yu, Jia Zhou, Christopher J. Branford‐White, Huali Nie, Li‐Min Zhu, Deng‐Guang Yu, Ji Yu, Yifeng Li, Mulian Zheng and Cheng Jiang and has published in prestigious journals such as Molecular Cell, Gastroenterology and Journal of Medicinal Chemistry.

In The Last Decade

Zonghui Ma

29 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zonghui Ma China 14 231 67 48 46 44 29 494
Qiurong Zhang China 17 308 1.3× 64 1.0× 81 1.7× 359 7.8× 41 0.9× 94 887
Peiyao Yu China 8 89 0.4× 45 0.7× 18 0.4× 15 0.3× 11 0.3× 21 357
Yukari Arai Japan 12 114 0.5× 52 0.8× 110 2.3× 216 4.7× 28 0.6× 22 600
Zhengyu Huang China 16 249 1.1× 73 1.1× 7 0.1× 26 0.6× 18 0.4× 60 719
Davinder Singh India 9 147 0.6× 37 0.6× 49 1.0× 23 0.5× 13 0.3× 36 406
Shengnan Huang China 15 196 0.8× 19 0.3× 36 0.8× 27 0.6× 3 0.1× 35 548
Mingxin Shi United States 15 246 1.1× 39 0.6× 66 1.4× 28 0.6× 2 0.0× 30 828
Mirko Hadžija Croatia 10 101 0.4× 38 0.6× 8 0.2× 23 0.5× 11 0.3× 42 488
Simin Xia China 14 346 1.5× 50 0.7× 24 0.5× 25 0.5× 3 0.1× 27 760
Xianwu Liu China 14 157 0.7× 30 0.4× 12 0.3× 20 0.4× 6 0.1× 20 652

Countries citing papers authored by Zonghui Ma

Since Specialization
Citations

This map shows the geographic impact of Zonghui Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zonghui Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zonghui Ma more than expected).

Fields of papers citing papers by Zonghui Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zonghui Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zonghui Ma. The network helps show where Zonghui Ma may publish in the future.

Co-authorship network of co-authors of Zonghui Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Zonghui Ma. A scholar is included among the top collaborators of Zonghui Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zonghui Ma. Zonghui Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Zonghui, Zhiqing Liu, Cun Zhang, et al.. (2025). Orally Bioavailable BRD4 BD1 Inhibitor ZL0516 Effectively Suppresses Colonic Inflammation in Animal Models of Inflammatory Bowel Disease. ACS Pharmacology & Translational Science. 8(4). 1152–1167. 3 indexed citations
2.
Ma, Zonghui, et al.. (2025). Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach. Journal of Medicinal Chemistry. 68(7). 6897–6915. 7 indexed citations
3.
Skibba, Melissa, Zonghui Ma, Carole L. Wilson, et al.. (2025). An orally bioavailable BRD4 inhibitor disrupts expansion of a pathogenic epithelial-mesenchymal niche in bleomycin-induced fibrosis. Respiratory Research. 26(1). 221–221. 1 indexed citations
4.
Ma, Zonghui, et al.. (2024). BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease. Advances in pharmacology. 101. 203–236. 3 indexed citations
5.
Ma, Zonghui, et al.. (2023). RIPTACs: A groundbreaking approach to drug discovery. Drug Discovery Today. 28(11). 103774–103774. 14 indexed citations
6.
Shah, Mansi, Zonghui Ma, Haiying Chen, et al.. (2023). DEVELOPMENT OF NANOPARTICLE-ENCAPSULATED BRD4 INHIBITORS FOR NOVEL EPIGENETIC THERAPEUTICS OF IBD. Inflammatory Bowel Diseases. 29(Supplement_1). S4–S4. 1 indexed citations
7.
Shah, Mansi, Zonghui Ma, Haiying Chen, et al.. (2023). DEVELOPMENT OF NANOPARTICLE-ENCAPSULATED BRD4 INHIBITORS FOR NOVEL EPIGENETIC THERAPEUTICS OF IBD. Gastroenterology. 164(4). S5–S6. 1 indexed citations
8.
Wu, Shwu‐Yuan, Hsien‐Tsung Lai, N. Sanjib Banerjee, et al.. (2023). IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors. Molecular Cell. 84(2). 202–220.e15. 11 indexed citations
9.
Ma, Zonghui, et al.. (2021). Discovery of benzimidazole derivatives as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity. Bioorganic & Medicinal Chemistry. 46. 116352–116352. 13 indexed citations
10.
Ma, Zonghui, et al.. (2021). Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy. European Journal of Medicinal Chemistry. 216. 113247–113247. 42 indexed citations
11.
12.
Yu, Yifan, et al.. (2020). Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery. European Journal of Medicinal Chemistry. 200. 112426–112426. 50 indexed citations
13.
Li, Bingyan, et al.. (2020). Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors. European Journal of Medicinal Chemistry. 209. 112940–112940. 29 indexed citations
14.
Ma, Zonghui, Guo‐Kai Wang, Feng-Qing Xu, et al.. (2019). Chemical constituents from plant endophytic fungus Alternaria alternata. Natural Product Research. 35(7). 1199–1206. 14 indexed citations
15.
Zheng, Mulian, et al.. (2017). A Study on Evaluation and Application of Snowmelt Performance of Anti-Icing Asphalt Pavement. Applied Sciences. 7(6). 583–583. 32 indexed citations
16.
Xiong, Feng, et al.. (2016). Lack of Association Found betweenHelicobacter pyloriInfection and Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Retrospective Study. Gastroenterology Research and Practice. 2016. 1–7. 13 indexed citations
17.
Zheng, Mulian, et al.. (2016). Laboratory evaluation of long-term anti-icing performance and moisture susceptibility of chloride-based asphalt mixture. International Journal of Pavement Research and Technology. 9(2). 140–148. 22 indexed citations
18.
Qin, Mingze, Tingting Wang, Zonghui Ma, et al.. (2015). Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant. European Journal of Medicinal Chemistry. 104. 115–126. 16 indexed citations
19.
Nie, Huali, Zonghui Ma, Christopher J. Branford‐White, et al.. (2009). Polyacrylonitrile fibers efficiently loaded with tamoxifen citrate using wet-spinning from co-dissolving solution. International Journal of Pharmaceutics. 373(1-2). 4–9. 26 indexed citations
20.
Ma, Zonghui, et al.. (2008). Microencapsulation of tamoxifen: Application to cotton fabric. Colloids and Surfaces B Biointerfaces. 69(1). 85–90. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qiurong Zhang Breakdown of academic impact, for papers by Peiyao Yu Breakdown of academic impact, for papers by Yukari Arai Breakdown of academic impact, for papers by Zhengyu Huang Breakdown of academic impact, for papers by Davinder Singh Breakdown of academic impact, for papers by Shengnan Huang Breakdown of academic impact, for papers by Mingxin Shi Breakdown of academic impact, for papers by Mirko Hadžija Breakdown of academic impact, for papers by Simin Xia Breakdown of academic impact, for papers by Xianwu Liu
Rankless by CCL
2026